# VC Research Progress Tracker

**Fund/VC**: Hyperion Ventures I LP
**Started**: 2025-01-11
**Last Updated**: 2025-01-12
**Status**: ✅ **COMPLETE**

---

## Phase 1A: GP Research

**GPs Identified**: 2 (Dillon Dunteman, Henry Bellew)

- [x] Dillon Dunteman (completed: 2025-01-11)
- [x] Henry Bellew (completed: 2025-01-11)

**Progress**: 2/2 complete ✅

**Output**: research/people/research-summary.md (26,147 bytes) + 5 source files

---

## Phase 1B: Company Research

### Tier 1 Companies (Priority Research)

**Total**: 5 companies

- [x] Quantinuum (completed: 2025-01-12)
- [x] Figure AI (completed: 2025-01-11)
- [x] Normal Computing (completed: 2025-01-11)
- [x] Dirac (completed: 2025-01-11)
- [x] Scout AI (completed: 2025-01-11)

**Progress**: 5/5 complete ✅

### Tier 2 Companies (Up-and-Comers)

**Total**: 9 companies (note: Scout listed in both tiers per dataroom)

- [x] Haiqu (completed: 2025-01-11)
- [x] Hephaestus (completed: 2025-01-11)
- [x] Innerworks (completed: 2025-01-11)
- [x] Natrion (completed: 2025-01-11)
- [x] Emerge (completed: 2025-01-11)
- [x] Mesh Optical (completed: 2025-01-11)
- [x] Biofire (completed: 2025-01-11)
- [x] Marathon Fusion (completed: 2025-01-11)
- [x] Scout (completed: 2025-01-11)

**Progress**: 9/9 complete ✅

**Output**: 14 research-summary.md files + ~60-80 source markdown files across research/deals/tier-1/ and research/deals/tier-2/

---

## Phase 1C: GP-Company Cross-Reference

**Status**: ✅ **COMPLETE** (2025-01-12)

**Tier 1**: 5/5 companies completed
- [x] Figure AI - Dataroom case study analyzed, external validation attempted (WebSearch unavailable)
- [x] Normal Computing - Dataroom case study + testimonial analyzed, external validation attempted
- [x] Dirac - Dataroom case study + testimonial analyzed, external validation attempted
- [x] Scout AI - Dataroom testimonial analyzed, external validation attempted
- [x] Quantinuum - Dataroom case study + testimonial analyzed (completed earlier)

**Tier 2**: 9/9 companies completed (previously done)
- All companies analyzed for GP mentions, documented in individual research-summary.md files

**Challenges**: WebSearch tool unavailable during Phase 1C, preventing external validation of GP claims. All GP evidence remains dataroom-only (Tier 3 sources). Documented verification attempts and recommended follow-up actions in each company file.

**Output**: GP mentions sections added/updated in all 14 research-summary.md files

---

## Phase 2: Analysis & Synthesis

- [x] GP-Company Relationships Matrix (completed: 2025-01-12)
- [x] Portfolio Quality Assessment (completed: 2025-01-12)
- [x] Executive Summary (completed: 2025-01-12)

**Progress**: 3/3 complete ✅

**Output**:
- research/analysis/gp-relationships.md (23,738 bytes) - Comprehensive GP-company cross-reference with Tier 1 + Tier 2 integrated analysis
- research/analysis/portfolio-assessment.md (full detailed analysis) - Portfolio quality scoring, company performance assessment, risk analysis
- research/outputs/executive-summary.md (primary deliverable) - 2-3 page concise summary for stakeholder review

---

## Completion Summary

**Status**: ✅ **COMPLETE**
**Completion Date**: January 12, 2025
**Total Time Invested**: ~10-12 hours (across 2 days)

**Outputs Created**:
- ✅ **2 GPs researched** → research/people/research-summary.md (+ 5 source files)
- ✅ **5 Tier 1 companies researched** → research/deals/tier-1/{company}/ (research-summary.md + sources/)
- ✅ **9 Tier 2 companies researched** → research/deals/tier-2/{company}/ (research-summary.md + sources/)
- ✅ **GP-Company Relationships Matrix** → research/analysis/gp-relationships.md (Tier 1 + Tier 2 integrated, 23,738 bytes)
- ✅ **Portfolio Quality Assessment** → research/analysis/portfolio-assessment.md (comprehensive scoring and analysis)
- ✅ **Executive Summary** → research/outputs/executive-summary.md (PRIMARY DELIVERABLE)
- ✅ **Supporting Files**: research/gp-list.md, research/company-clusters.md, research/research-progress.md (this file)

**Key Deliverable**: **research/outputs/executive-summary.md**
Read this first for concise 2-3 page overview of portfolio quality, GP assessment, and recommendations.

**For Deep Dive**:
- Full company research: research/deals/tier-1/ and research/deals/tier-2/
- GP relationship analysis: research/analysis/gp-relationships.md
- Detailed portfolio assessment: research/analysis/portfolio-assessment.md

---

## Key Findings (Executive Summary)

1. **Portfolio Driven by Single Outlier**: Figure AI (94x MOIC) represents >50% of portfolio value. Binary outcome: top-decile IF executes OR compression if $39.5B valuation unsustainable.

2. **Deeptech Thesis Coherence**: Strong "AI + hard science" focus with tier-1 co-investor validation (Founders Fund, Coatue, Microsoft, NVIDIA, Bezos).

3. **GP Value-Add Entirely Unverified**: 100% of Dillon evidence from dataroom-only sources. Zero external validation. Urgent founder interviews required outside fundraising context.

4. **Henry Bellew Zero Involvement**: No mentions across 14 companies (including 5 with 94x-6.7x MOICs). Raises serious GP team utilization questions.

5. **Overall Assessment**: **7.5/10 (Strong)** - High-quality portfolio with exceptional paper returns BUT significant caveats around valuation risk, concentration, and unverified GP claims.

---

## Critical Next Steps

**URGENT VALIDATION REQUIRED**:
1. **Dirac-Founders Fund Introduction**: Verify with Trae Stephens or Fil Aronshtein (HIGHEST PRIORITY)
2. **Normal Computing Advisor Role**: Interview Faris Sbahi + referred hires to confirm value-add
3. **Figure Tamarack Relationship**: Verify with Tamarack Global partners if Dillon relationship was critical
4. **Quantinuum Ongoing Value**: Interview Ilyas Khan outside fundraising context
5. **Henry Bellew Role**: Clarify division of labor and contribution to fund

**DATAROOM CONCERNS**:
- Natrion GM "customer" claim FALSE (GM is investor, not customer)
- Emerge Apple/Meta "acquisition" claim UNVERIFIED (zero public evidence)
- Recommend full dataroom review with skeptical lens

**FOLLOW-UP RESEARCH**:
- Figure AI valuation model and revenue projections
- Scout vs. Scout AI naming conflict resolution
- External validation when WebSearch available

---

## Workflow Performance Metrics

**Efficiency**:
- Total hours invested: ~10-12 hours (target: 8-12 hours) ✅
- Average time per Tier 1 company: ~60 minutes ✅
- Average time per Tier 2 company: ~30-40 minutes ✅
- Average sources per Tier 1: 5-7 ✅
- Average sources per Tier 2: 3-4 ✅

**Quality**:
- All companies meet source quality thresholds ✅
- GP mentions searched for all 14 companies ✅
- External validation attempted (WebSearch unavailable, documented) ✅
- Analysis documents cite specific evidence ✅
- Portfolio assessment includes scoring framework ✅
- Executive summary concise and actionable ✅

**Resumability**:
- Progress tracker kept updated ✅
- File system reflects completion status ✅
- All phases checkpointed ✅

---

## Lessons Learned / Workflow Notes

1. **WebSearch Unavailability**: External validation blocked during Phase 1C. Documented attempts and fallback to PATH 2 (Dataroom Only) format. Recommend retry validation when WebSearch available.

2. **Dataroom Credibility**: Identified 2 material misrepresentations (Natrion, Emerge) early, which informed skeptical approach to other claims. Emphasizes importance of external validation.

3. **Tier 1 Prioritization**: Completing all Tier 1 first (5/5) before Tier 2 proved efficient for understanding portfolio priorities and GP involvement patterns.

4. **Company Clustering**: Sector groupings (research/company-clusters.md) helped identify patterns but limited reuse opportunities given diverse sectors.

5. **GP Analysis Integration**: Adding Tier 1 to gp-relationships.md after Tier 2 required significant updates but revealed critical concentration pattern (Dillon 100% Tier 1 involvement).

---

## Questions / Issues Encountered

1. **Scout vs. Scout AI Naming**: Two companies with similar names (both in sales/GTM AI space). Tier 1 = "Scout AI", Tier 2 = "Scout". Requires clarification if same company or different entities.

2. **Henry Bellew Absence**: Zero portfolio mentions unprecedented. Division of labor unclear. Raised as critical finding in all analysis documents.

3. **WebSearch Tool Unavailability**: Prevented external validation of GP claims during Phase 1C. Used fallback approach (document attempts, mark as unverified, recommend retry).

4. **Dataroom Discrepancies**: Natrion GM claim and Emerge acquisition claim both false/unverified. Raised as credibility concern throughout analysis.

---

**Workflow Completion Confirmed**: ✅ All phases complete (1A, 1B, 1C, 2.1, 2.2, 2.3)
**Primary Deliverable Location**: research/outputs/executive-summary.md
**Workflow Version**: v2.0 (Streamlined)
**Completion Date**: January 12, 2025
